Ackermann R, Kaiser G
Ciba-Geigy Ltd, Pharmaceuticals Division, Basle, Switzerland.
Biomed Environ Mass Spectrom. 1989 Aug;18(8):558-62. doi: 10.1002/bms.1200180808.
A specific and sensitive gas chromatographic/mass spectrometric method was developed and validated for the quantitative determination of the aromatase inhibitor CGS 16 949 in plasma and urine. A deuterium-labelled analogue of CGS 16 949 was used as internal standard. The analysis of spiked samples demonstrated the good accuracy and precision of the method. For both plasma and urine, the limit of quantification (LOQ: coefficient of variation (CV) = 10%) and the limit of detection (LOD: CV = 100%) were estimated to be 5 and 1 nmol l-1, respectively. The method was applied to the determination of unchanged CGS 16 949 in plasma and urine of a healthy volunteer orally dosed with 1 mg of CGS 16 949 A.
建立并验证了一种特异性强且灵敏的气相色谱/质谱法，用于定量测定血浆和尿液中的芳香化酶抑制剂CGS 16 949。使用CGS 16 949的氘代类似物作为内标。加标样品分析表明该方法具有良好的准确度和精密度。对于血浆和尿液，定量限（LOQ：变异系数（CV）= 10%）和检测限（LOD：CV = 100%）分别估计为5和1 nmol l-1。该方法应用于口服1 mg CGS 16 949 A的健康志愿者血浆和尿液中未变化的CGS 16 949的测定。
